FDA Approves Targeted Therapy for Metastatic Pancreatic Cancer Following UCLA-led Study
August 27, 2026
August 27, 2026
LOS ANGELES, California, Aug. 27 (TNSjou) -- The UCLA Health issued the following news release:
* * *
FDA approves targeted therapy for metastatic pancreatic cancer following UCLA-led study
Study shows RAS inhibitor significantly improves survival, tumor response and quality of life compared with chemotherapy
-
The U.S. Food and Drug Administration has approved daraxonrasib, to be sold under the brand name Rasonque, for the treatme . . .
* * *
FDA approves targeted therapy for metastatic pancreatic cancer following UCLA-led study
Study shows RAS inhibitor significantly improves survival, tumor response and quality of life compared with chemotherapy
-
The U.S. Food and Drug Administration has approved daraxonrasib, to be sold under the brand name Rasonque, for the treatme . . .